Business Valuation

Initial Public Offering (IPO)

Congratulations to Green Future Food Hydrocolloid Marine Science Co. Ltd. (stock code: 1084.HK) on its successful listing on the Main Board of HKEx on 17 October 2019. With regard to this listing application, AVISTA Group is honored to be engaged in providing valuation services in relation to the fair value of financial instruments, purchase price allocation and goodwill impairment tests for financial reporting purpose.
 
<img src="../../../../../uploads/greenfuture_eng_1a530a408f.jpeg" width="700" />

Congratulations to Green Future Food Hydrocolloid Marine Science Co., Ltd. (Stock Code: 1084.HK) on its Successful Listing

Chagee Holdings Limited, originated in Yunnan, China, primarily engaged in the provision of the Chinese-style tea drinks brand – Chagee. It is a leading premium tea drinks brand, which focuses on premium and freshly-made tea, aiming to integrate Eastern culture with the heritage and innovation of tea drinks, creating a new style of Eastern tea house. Founded in 2017, Chagee has expanded from Southwest China to over 30 provinces and autonomous regions, and has opened stores in Southeast Asia, including Malaysia, Singapore, and Thailand, reaching a total of 6,440 stores by 2024.
 
With regard to this listing application, AVISTA Group is honored to be engaged in providing valuation services related to preferred shares, employee stock option and incremental borrowing rates assessment for financial reporting purposes.
 
Congratulations again to Chagee Holdings Limited (CHA.NASDAQ) on its successful listing. The issue price is USD28 per share, and the amount of funds raised is USD411 million.
 
<img src="../../../../../uploads/Slide1_5ee0e92d14.JPG" alt="" width="960" height="720" />

banner1

Congratulations to Chagee Holdings Limited (CHA.NASDAQ) on its successful Listing on NASDAQ on 17 April 2025

Duality Biotherapeutics is a clinical-stage biotech company dedicated to the discovery and development of next-generation ADC to treat cancer and autoimmune diseases. The company has successfully built several cutting-edge ADC technology platforms with global intellectual property rights. Leveraging a robust pipeline, the company is conducting multiple global clinical trials across 17 countries, has enrolled over 2000 patients for multiple clinical-stage ADC candidates.
 
With regard to this listing application, AVISTA Group is honoured to be engaged in providing valuation services related to preferred stock, employee stock option and intangible asset impairment testing for financial reporting purposes. 
Congratulations again to Duality Biotherapeutics, Inc.(9606.HK) on its successful listing. The issue price is HKD 94.6 per share, and the amount of funds raised is HKD 1.51 billion.
<img src="../../../../../uploads/Slide1_4c742f3d87.JPG" alt="" width="960" height="720" />

Congratulations to Duality Biotherapeutics, Inc.(9606.HK) on its Successful Listing

AVISTA Group was honored to be invited by Hong Kong Securities and Investment Institute (HKSI) to serve as the project sponsor of Institute Case Competition 2025. Our Managing Partner, Mr. Vincent Pang, and Director of Risk Management Advisory Services, Ms. Sabrina Lam, took on the role of coaches, guiding and mentoring the talented participants throughout the competition.
This year's competition focused on a sustainability research project, with the theme centered around "Identifying best practices in financial institutions' climate disclosures aligned with TCFD and/or IFRS S2, along with an analysis of their current progress in Scope 3 emissions reporting." Mr. Pang and Ms. Lam have chosen one group of the best performers among five to advance to the semi-final round. All groups demonstrated strong analytical skills and delivered outstanding performances in the initial round.
We extend our heartfelt thanks to all the participating groups for their hard work and dedication. Congratulations to all the semi-finalists and finalists for their remarkable achievements in the competition. As a leading professional advisory firm, AVISTA is privileged to contribute our expertise and support the development of future business leaders through initiatives like the HKSI Institute Case Competition.
 
<img src="../../../../../uploads/Finalist_2_037420e990.JPG" alt="" width="1000" height="667" />